Kalipada O Pahan

US Patent:

20130303564, Nov 14, 2013

Filed:

May 13, 2013

Appl. No.:

13/892915

Inventors:

Kalipada Pahan - Skokie IL, US

International Classification:

A61K 31/4709
A61K 31/435
A61K 31/417
A61K 31/192
A61K 31/216

US Classification:

514290, 514570, 514510, 514400, 514539, 514312

Abstract:

Provided herein are methods and materials for treating neurodegenerative disorders. The methods may use inhibitors of small G-proteins, such as p21, p21, or the combination thereof. The small G-proteins may reside in glial cells and/or the substantia

US Patent:

20220363722, Nov 17, 2022

Filed:

Mar 21, 2022

Appl. No.:

17/699792

Inventors:

- Chicago IL, US
Kalipada Pahan - Skokie IL, US

International Classification:

C07K 14/005
A61K 38/16
A61P 31/14

Abstract:

Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.

US Patent:

20220313646, Oct 6, 2022

Filed:

Jul 13, 2020

Appl. No.:

17/627391

Inventors:

- Chicago IL, US
Kalipada Pahan - Skokie IL, US

International Classification:

A61K 31/235
A61K 9/00
A61K 47/24
A61P 25/28

Abstract:

The present disclosure generally relates to improved pharmaceutical compositions useful for the treatment of diseases and disorders. More particularly, the disclosure relates to pharmaceutical compositions comprising glyceryl tribenzoate and/or glyceryl dibenzoate for the treatment of neurodegenerative disorders and peripheral diseases.

US Patent:

20230046776, Feb 16, 2023

Filed:

Oct 18, 2022

Appl. No.:

17/968264

Inventors:

- Chicago IL, US
Kalipada Pahan - Skokie IL, US

International Classification:

A61K 31/439
A61P 25/16
A61K 9/00
A61K 31/4178
A61K 31/499
A61K 31/506

Abstract:

The present invention generally relates to compositions and methods for treating a neurological disorder in a subject, the method including administering to the subject in need of such treatment a composition including a therapeutically effective amount of a CCR5 antagonist. The CCR5 antagonist may be, for example, maraviroc. The neurological disorder may be, for example, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies or multiple system atrophy.

US Patent:

20230037062, Feb 2, 2023

Filed:

Sep 29, 2020

Appl. No.:

17/036138

Inventors:

- Chicago IL, US
Kalipada Pahan - Skokie IL, US

Assignee:

RUSH UNIVERSITY MEDICAL CENTER - Chicago IL

International Classification:

A61K 31/616
A61K 31/07
A61K 31/192
A61K 31/22
A61K 31/366
A61K 45/06
A61K 31/203
A61K 31/216
A61K 31/505
A61K 31/404
A61K 31/47
A61K 31/40
A61K 31/222

Abstract:

One aspect of the invention provides a method for treatment of a lysosomal storage disorder. The method may include administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent that mediates upregulation of Transcription Factor EB. In one embodiment, the composition includes a fibrate, such as gemfibrozil or fenofibrate. In another embodiment, the composition also includes all-trans retinoic acid or vitamin A.

US Patent:

20210401856, Dec 30, 2021

Filed:

Nov 5, 2019

Appl. No.:

17/290798

Inventors:

- Chicago IL, US
Kalipada PAHAN - Skokie IL, US

Assignee:

Rush University Medical Center - Chicago IL

International Classification:

A61K 31/616
A61K 9/00
A61P 25/28

Abstract:

Provided herein are methods for delivering acetylsalicylic acid via nasal delivery for the treatment of neurodegenerative and lysosomal storage disorders, such as Alzheimer's disease and Batten disease.

US Patent:

20210361740, Nov 25, 2021

Filed:

Dec 28, 2018

Appl. No.:

16/966277

Inventors:

- Chicago IL, US
Kalipada Pahan - Skokie IL, US

Assignee:

Rush university Medical Center - Chicago IL

International Classification:

A61K 38/17
A61K 47/64
A61K 9/00
A61P 25/28
A61P 25/16

Abstract:

The present invention generally relates to methods for treating neurological and other disorders, including autoimmune disorders. One aspect of the invention relates to a method of treating a disorder in which Toll-like Receptor 2 (TLR2) activation by binding to myeloid differentiation primary response 88 (MyD88) plays a role in disease pathogenesis. In one embodiment the method includes the administration of a composition, including a peptide sequence, that inhibits the activation of TLR2 by MyD88.

US Patent:

20210324004, Oct 21, 2021

Filed:

Dec 23, 2020

Appl. No.:

17/133035

Inventors:

- Chicago IL, US
Kalipada PAHAN - Skokie IL, US

Assignee:

Rush University Medical Center - Chicago IL

International Classification:

C07K 7/06
A61K 9/00
A61P 31/14
A61K 38/08
A61K 38/10
C07K 7/08

Abstract:

Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.